CEACAM5 and neoplasm: Early pre-clinical and clinical data suggest that TCBs against the carcinoembryonic antigen (CEA), which are a known CRC biomarker, can lead to up-regulated expression of PD-L1, increase intra-tumoral lymphocytes and augment anti-tumor activity [38].